Pages that link to "Q95383393"
Jump to navigation
Jump to search
The following pages link to Immunohistochemical analysis of human equilibrative nucleoside transporter-1 (hENT1) predicts survival in resected pancreatic cancer patients treated with adjuvant gemcitabine monotherapy (Q95383393):
Displaying 18 items.
- hENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: a systematic review (Q26862139) (← links)
- Systemic therapies for pancreatic cancer--the role of pharmacogenetics (Q27021716) (← links)
- Equilibrative nucleoside transporters-A review (Q30244329) (← links)
- Translational research in pancreatic ductal adenocarcinoma: current evidence and future concepts (Q34067863) (← links)
- Nucleoside transporter proteins as biomarkers of drug responsiveness and drug targets. (Q35066350) (← links)
- Prognostic value of human equilibrative nucleoside transporter1 in pancreatic cancer receiving gemcitabin-based chemotherapy: a meta-analysis (Q35086475) (← links)
- Fasting cycles potentiate the efficacy of gemcitabine treatment in in vitro and in vivo pancreatic cancer models. (Q36210934) (← links)
- Enhancing Drug Efficacy and Therapeutic Index through Cheminformatics-Based Selection of Small Molecule Binary Weapons That Improve Transporter-Mediated Targeting: A Cytotoxicity System Based on Gemcitabine (Q36342657) (← links)
- Human Equilibrative Nucleoside Transporter 1 Expression in Endoscopic Ultrasonography-Guided Fine-Needle Aspiration Biopsy Samples Is a Strong Predictor of Clinical Response and Survival in the Patients With Pancreatic Ductal Adenocarcinoma Undergoi (Q36822149) (← links)
- A meta-analysis of gemcitabine biomarkers in patients with pancreaticobiliary cancers (Q37268613) (← links)
- Transport properties of pancreatic cancer describe gemcitabine delivery and response (Q37679971) (← links)
- Predictive role of human equilibrative nucleoside transporter 1 in patients with pancreatic cancer treated by curative resection and gemcitabine-only adjuvant chemotherapy (Q38686035) (← links)
- Precision Medicine and Pancreatic Cancer: A Gemcitabine Pathway Approach (Q39283216) (← links)
- The evolution into personalized therapies in pancreatic ductal adenocarcinoma: challenges and opportunities. (Q48098689) (← links)
- Overcoming tumor cell chemoresistance using nanoparticles: lysosomes are beneficial for (stearoyl) gemcitabine-incorporated solid lipid nanoparticles (Q49387560) (← links)
- Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma (Q50569337) (← links)
- Functional Characterization of the Saccharomyces cerevisiae Equilibrative Nucleoside Transporter 1 (ScENT1). (Q51736626) (← links)
- Screening miRNAs associated with resistance gemcitabine from exosomes in A549 lung cancer cells (Q92354790) (← links)